Pharmacist-Led Obesity Management Improves Cardiometabolic Outcomes vs Traditional Care

Investigators at the American Pharmacists Association Annual Meeting and Exposition 2026 in Los Angeles, California, presented real-world poster evidence demonstrating that pharmacist-led obesity management programs can achieve comparable or greater improvements in cardiometabolic outcomes compared with traditional care models.¹

The retrospective study, conducted by researchers from the University of Kansas School of Pharmacy in collaboration with Ascension Via Christi, evaluated outcomes among adults receiving pharmacist-led care vs traditional provider-led obesity management.¹

Pharmacist-Led Care Demonstrates Improved Glycemic Outcomes

The analysis included 678 patients: 110 in the pharmacist-led group and 568 in the traditional care group. Baseline characteristics were generally similar between groups, although patients managed by pharmacists had higher baseline hemoglobin A_1c (HbA_1c) levels, suggesting a potentially higher-risk population.¹

Despite this, pharmacist-led care was associated with a significantly greater reduction in HbA_1c compared with traditional care (median change: −0.35% vs 0.00%; P = .002). This finding is particularly notable given the higher baseline HbA_1c in the pharmacist group, indicating that pharmacist intervention may be especially beneficial in patients with more complex metabolic needs.¹

Lipid and Liver Outcomes Highlight Broader Impact

Beyond glycemic control, pharmacist-led care was associated with improvements across several cardiometabolic markers. Reductions in lipid parameters—including total cholesterol, low-density lipoprotein, and triglycerides—were greater in the pharmacist-managed group, indicating a potential advantage in comprehensive cardiovascular risk reduction.¹

Investigators also observed modest improvements in liver enzymes, particularly alanine aminotransferase, in the pharmacist-led cohort. Although these findings warrant further investigation, they may allude to additional metabolic benefits associated with pharmacist-driven interventions.¹

Blood pressure reductions were observed in both groups, with similar changes between pharmacist-led and traditional care. This observation suggests that both models can effectively address hypertension when incorporated into obesity management strategies.¹

Pharmacists Enhance Access and Individualized Care

These results align with broader evidence demonstrating that pharmacist involvement in chronic disease management can improve glycemic control through medication optimization, adherence support, and patient education.²

The study authors emphasized that pharmacist-led care models offer a more individualized and responsive approach to obesity management, often delivered through collaborative practice agreements. These models allow pharmacists to adjust medications, monitor progress, and provide ongoing counseling, helping to address gaps in traditional care delivery.

Importantly, obesity remains a complex, chronic condition requiring sustained, multidisciplinary management. The prevalence of obesity in the United States continues to rise, contributing to increased risk for diabetes, cardiovascular disease, and other comorbidities.³

Pharmacists are well positioned to support patients through frequent touchpoints, medication management, and lifestyle counseling, particularly in ambulatory care settings where access to care may be limited.²

Implications for Expanding Pharmacist-Led Models

Although the study was limited by its retrospective design, the findings support the scalability of pharmacist-led obesity management programs. The authors noted that care delivered under collaborative practice agreements represents a feasible strategy to expand access to high-quality obesity care in real-world settings.¹

For pharmacists, these results reinforce an expanding role in the management of obesity and cardiometabolic disease. By leveraging their expertise in pharmacotherapy and patient counseling, pharmacists can help drive meaningful improvements in outcomes while addressing gaps in traditional care models.

As health systems continue to explore team-based approaches to chronic disease management, pharmacist-led interventions may play an increasingly central role in improving both clinical outcomes and patient access to care.

REFERENCES

1. Newell BJ, Jones KM, Presnell EN, Melton BL. Pharmacist-led obesity management in adults: a real-world retrospective comparison with traditional care. Presented at: American Pharmacists Association Annual Meeting and Exposition 2026; March 27-30, 2026; Los Angeles, CA.

2. Alhomoud IS, Cook E, Patel D, Brown RE, Dixon DL. Effect of pharmacist interventions on the management of overweight and obesity: a systematic review. J Am Pharm Assoc (2003). 2024;64(3):102058. doi:10.1016/j.japh.2024.102058

3. Emmerich SD, Fryar CD, Stierman B, Ogden CL. Obesity and severe obesity prevalence in adults: United States, August 2021-August 2023. NCHS Data Brief. 2024:(508):10.15620/cdc/159281. doi:10.15620/cdc/159281